Loading…
← CockpitCompetitor Analysis › 603334.SS Suzhou Fengbei Biotech Stock Co., Ltd. Class AOpen in the cockpit ↗

Suzhou Fengbei Biotech Stock Co., Ltd. Class A603334.SSCompetitor analysis, valuation and peers

China · CNY·Materials›Chemicals: Agricultural
Momentum laggard 7
Mkt cap
$586M
US dollars, full cap
$/day
$10.3M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-2.1 pp
WACC 8.4%
Hurdle
n/a
no reverse DCF
Close · CNYCN¥27.36
1D+4.5%
1W+7.2%
1M-18.1%
3M-18.9%
6M-43.6%
YTD-34.5%
1Yn/a
ATR %5.4%
52w lowhigh64.0% off high

What Suzhou Fengbei Biotech Stock does

Employees: 395

Suzhou Fengbei Biotech Stock at a glance

Size Suzhou Fengbei Biotech Stock (603334.SS) is a China Materials company (Chemicals: Agricultural) with a market value of $586M, the 3482nd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥27.36 on 6 Nov 2026.

Performance Over six months the shares fell 43.6%, against -22.5% for the median peer and -16.4% for the China market (cap-weighted) — lowest of 21 in its peer set.

Growth Revenue grew 62.8% over the last twelve months (peer median +4.6%); the operating margin is 3.6% (peer median 4.0%).

Valuation It trades at 1.1× enterprise value to sales against a peer median of 1.5× (10th cheapest of 21).

Capital Return on invested capital runs 2.1 points below its cost of capital (8.4% WACC).

Relative performance

608010011 May 202611 Aug 20266 Nov 2026Peer median 78603334.SS 58
Six months, rebased to 100: Suzhou Fengbei Biotech Stock against the median of its 20 peers (local-currency closes).

Suzhou Fengbei Biotech Stock financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenuen/aCN¥3.17BCN¥1.95BCN¥1.73BCN¥1.71B
Revenue growth—+63%+13%+1%—
Gross profitn/aCN¥248MCN¥214MCN¥233MCN¥226M
EBITDAn/aCN¥147MCN¥134MCN¥137MCN¥144M
Net incomen/aCN¥141MCN¥124MCN¥130MCN¥133M
Free cash flown/a-CN¥50.8M-CN¥57.1M-CN¥5.62M-CN¥10.4M
Capital expendituren/aCN¥24.4MCN¥79.5MCN¥168MCN¥80.1M
Total debtCN¥296MCN¥308MCN¥340MCN¥267MCN¥283M

Quarterly statements and history in the cockpit →

Suzhou Fengbei Biotech Stock competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%-20%-10%0%GSFCRCF002556600796600228499700071317124996603639002391LXU002734KRISHANA002538603395600227EPIGRAL603334.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Suzhou Fengbei Biotech Stock is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%+80%1×2×3×GSFCRCF002556600796600228499700071317120027494996603639002391600731LXU002734KRISHANA603395600227EPIGRAL603334.SSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Suzhou Fengbei Biotech Stock is the large dot.

Suzhou Fengbei Biotech Stock competitors and peer comparison

How Suzhou Fengbei Biotech Stock compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Suzhou Fengbei Biotech Stock against its 20 peers (data as of 6 Nov 2026)
Measure603334.SSPeer medianRank in peer set
1-month return-18.1%-6.8%3rd lowest of 21
6-month return-43.6%-22.5%lowest of 21
Distance from 52-week high-64.0%-33.3%lowest of 21
Revenue growth (TTM)+62.8%+4.6%3rd highest of 21
Operating margin3.6%4.0%10th lowest of 21
EV / Sales1.1×1.5×10th cheapest of 21
ROIC minus cost of capital-2.1 pp-1.8 pp10th lowest of 21
Net debt / EBITDA-2.8×1.4×least indebted of 11

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Suzhou Fengbei Biotech Stock 603334.SSChina$586M-44%+63%4%1.1×n/an/a
Gujarat State Fertilizers & Chemicals GSFC.NSIndia$588M-22%+37%3%0.4×23.2%+3.2%
Rashtriya Chemicals & Fertilizers RCF.NSIndia$590M-23%+18%4%0.3×n/an/a
Anhui Huilong Agricultural Means of Production .Co 002556.SZChina$594M-31%0%1%0.5×8.7%-1.2%
Zhejiang Qianjiang Biochemical 600796.SSChina$629M-24%-2%11%3.2×7.8%-2.0%
Jiangxi Fanli Digital Technology 600228.SSChina$539M+39%+140%-7%4.7×n/an/a
Nihon Nohyaku 4997.TJapan$522M+6%+7%10%0.8×-7.1%+9.3%
Sdic Fengle Seed 000713.SZChina$664M-15%+10%2%1.1×12.2%+3.4%
Sinon 1712.TWTaiwan$514M-4%0%7%1.0×-4.3%+1.3%
Sichuan Guoguang Agrochemical 002749.SZChina$668M-24%-2%18%1.9×-8.5%+12.2%
Kumiai Chemical Industry 4996.TJapan$499M-17%+7%4%0.6×-8.5%+9.7%
Hailir Pesticides & Chemicals 603639.SSChina$463M-29%-9%1%1.1×n/an/a
Jiangsu Changqing Agrochemical 002391.SZChina$461M-28%-2%3%1.8×n/an/a
Hunan Haili Chemical Industry 600731.SSChina$459M-19%-24%11%1.5×-5.8%-3.6%
LSB Industries LXUUnited States$763M-24%+13%11%1.6×-0.8%+11.9%
Limin 002734.SZChina$778M-37%-6%8%1.4×-1.2%+0.6%
Krishana Phoschem KRISHANA.NSIndia$781M+79%+73%11%2.9×n/an/a
Anhui Sierte Fertilizer Industry 002538.SZChina$794M-15%+9%3%1.0×n/an/a
CNSIG Anhui Hongsifang Fertilizer 603395.SSChina$798M-23%+3%0%1.6×n/an/a
Guizhou Chitianhua 600227.SSChina$803M-22%-2%-5%2.7×10.3%+2.4%
Epigral EPIGRAL.NSIndia$418M-33%+13%15%1.6×n/an/a

Questions

Which companies are Suzhou Fengbei Biotech Stock's closest peers?
The cockpit's peer set: Gujarat State Fertilizers & Chemicals (GSFC.NS), Rashtriya Chemicals & Fertilizers (RCF.NS), Anhui Huilong Agricultural Means of Production .Co (002556.SZ), Zhejiang Qianjiang Biochemical (600796.SS), Jiangxi Fanli Digital Technology (600228.SS), Nihon Nohyaku (4997.T), Sdic Fengle Seed (000713.SZ), Sinon (1712.TW).
Is Suzhou Fengbei Biotech Stock expensive compared with its peers?
On ev / sales it trades at 1.1× against a peer median of 1.5×, 10th cheapest of 21 in its peer set.
How has Suzhou Fengbei Biotech Stock stock performed?
Over six months to 6 Nov 2026 the shares returned -43.6% against -22.5% for the median peer.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.